Access Bio엑세스바이오

Access Bio is still loss-making with sharply falling revenue, though it just announced a ₩5B diagnostic kit supply deal with a P&G affiliate.

Access Bio, a KOSDAQ-listed maker of rapid diagnostic tests, reported trailing twelve-month revenue of about ₩16.2B to H1 2026 against an operating loss of about ₩48.9B, so losses are far larger than sales. Revenue has fallen sharply from the 2022 peak of about ₩800B, and the shares are down 52.4% over one year, trading at ₩2,030 on 2026-10-21. The data does not include a forecast or analyst view.

What stands out

• Trailing revenue of about ₩16.2B against an operating loss of about ₩48.9B and a net loss of about ₩76.7B, with an operating margin of -302.5%.
• Revenue fell 73.3% in 2025 to about ₩22.0B, after falling in each year since 2022.
• Cash of about ₩154B against borrowings of about ₩29B, and free cash flow of about -₩40.6B over the trailing period.
• On 2026-10-20 the company disclosed a ₩5B supply contract for flu and COVID self-test kits with a P&G affiliate in the US, and news outlets reported the same deal.
• Foreign ownership is 4.8%, down slightly from 4.9% sixty days earlier, and 20-day net flows were led by retail buying while foreign investors were net sellers.

What to watch

• Whether the ₩5B P&G-affiliate contract is recognised as revenue and how it compares with the size of the trailing losses.
• The next quarterly or half-year filings, which should show whether operating losses are narrowing.
• A lawsuit filing and ruling was amended in July 2026; the data does not say what the case involves or its potential impact.